ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) announced its quarterly earnings data on Tuesday. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.01), Zacks reports.
ESSA Pharma Price Performance
NASDAQ EPIX opened at $1.61 on Wednesday. ESSA Pharma has a 12 month low of $1.40 and a 12 month high of $10.94. The stock has a 50 day moving average of $1.72 and a 200-day moving average of $3.67.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on the company. Oppenheimer cut ESSA Pharma from an “outperform” rating to a “market perform” rating in a report on Monday, November 4th. Piper Sandler cut ESSA Pharma from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $15.00 to $2.00 in a research note on Monday, November 4th. Finally, Jefferies Financial Group cut ESSA Pharma from a “buy” rating to a “hold” rating in a research note on Monday, November 4th.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Recommended Stories
- Five stocks we like better than ESSA Pharma
- What is the Hang Seng index?
- Shopify Confirms Stock Uptrend, New Highs in Sight
- 3 Stocks to Consider Buying in October
- Super Micro Computer’s Stock Is About to Make a Super Big Advance
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Will the Tariff Bump Lead to a Steel Trap?
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
